Company Overview - Baolait Medical Technology Co., Ltd. was established in 1993, focusing on the R&D, production, and sales of medical devices. It is recognized as a "National Industrialization Base for Multi-parameter Monitors" and a "National Champion Enterprise" in manufacturing [1][2]. - The company’s monitoring equipment is utilized in thousands of medical institutions, offering a wide range of products including integrated monitors, modular monitors, and portable monitors, as well as infusion pumps and ECG machines [1][2]. Product Development and Innovation - The company aims to enhance its monitoring products by integrating smart technology to address clinical needs and develop differentiated solutions [3]. - The D800 series of hemodialysis devices, featuring single, double, and triple pump models, supports real-time monitoring of vital signs and includes IoT capabilities for remote management [4]. Market Growth and Trends - The hemodialysis market is projected to grow, with 1.027 million patients expected in 2024, maintaining a compound annual growth rate (CAGR) of approximately 12% over the past decade [6]. - The domestic market for hemodialysis equipment saw sales growth in the first three quarters of 2025, driven by hospital operations and centralized procurement [6]. Regulatory Impact - The "Urological Medical Service Pricing Project Guidelines" issued in June 2025 will include monitoring parameters in the pricing of hemodialysis, benefiting the D800 series which meets these new requirements without additional modules [7]. Peritoneal Dialysis Market - The peritoneal dialysis market is also expanding, with 156,400 patients projected in 2024 and a CAGR of over 10% in the last decade. Challenges include cost and safety concerns, but increased policy support is expected to drive adoption [8][9]. - The company has launched automated home peritoneal dialysis machines and disposable tubing, with ongoing efforts to enhance marketing strategies for these products [9]. New Product Launches - Recent product launches include the D800 series, P series modular monitors, home peritoneal dialysis machines, and various other innovative medical devices, some of which have received industry accolades [10]. - The D800Plus is noted as the first domestic triple pump model, improving dialysis treatment outcomes through advanced technology [10]. Conclusion - Baolait Medical Technology is positioned to leverage its technological advantages in a growing market, supported by favorable policies and a commitment to innovation in medical devices [5][6][7].

Group 1 - The company Baolait (SZ 300246) announced that its ninth fifth board meeting was held on December 29, 2025, to discuss the proposal regarding not adjusting the conversion price of "Baolai Convertible Bonds" [1] - For the year 2024, Baolait's revenue composition is as follows: medical devices account for 69.34%, commercial activities account for 29.46%, and other businesses account for 1.2% [1] - As of the report, Baolait's market capitalization is 2.2 billion yuan [1] Group 2 - A new type of chip has been developed in China, which bypasses the restrictions on lithography machines and supports AI training and embodied intelligence, capable of mass production using mature processes of 28 nanometers and above [1]

广东宝莱特医用科技股份有限公司（以下简称"公司"）于 2025 年 12 月 29 日以通讯表决及现场会议相结合的方式召开第九届董事会第五次会议，会议 通知于 2025 年 12 月 25 日以电子邮件、电话及传真方式送达，公司董事会共有 董事九名，参与表决的董事共九名，符合《公司法》和《公司章程》的规定。 会议由公司董事长燕金元先生主持，经表决，审议通过了以下议案： 一、 审议通过了《关于不向下修正"宝莱转债"转股价格的议案》 根据《广东宝莱特医用科技股份有限公司创业板向不特定对象发行可转换公 司债券募集说明书》（以下简称"募集说明书"）中相关条款，截至 2025 年 12 月 29 日，公司股票在任意连续三十个交易日中至少有十五个交易日的收盘价低于 当期转股价格的 90%。 证券代码：300246 证券简称：宝莱特 公告编号：2025-087 债券代码：123065 债券简称：宝莱转债 广东宝莱特医用科技股份有限公司 第九届董事会第五次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 证券代码：300246 证券简称：宝莱特 公告编号：2025-0 ...

关于不向下修正"宝莱转债"转股价格的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 证券代码：300246 证券简称：宝莱特 公告编号：2025-088 债券代码：123065 债券简称：宝莱转债 广东宝莱特医用科技股份有限公司 （一）可转债发行上市基本情况 特别提示： 经深圳证券交易所创业板上市委2020年第8次审议会议审核通过，并经中国 证监会证监许可[2020]1831号文同意注册。公司于2020年9月4日向不特定对象发 行了219万张可转换公司债券，每张面值为人民币100元，发行总额为人民币2.19 亿元。 公司 2.19 亿元可转换公司债券于 2020 年 9 月 24 日起在深交所挂牌交易， 证券代码：300246 证券简称：宝莱特 公告编号：2025-088 债券代码：123065 债券简称：宝莱转债 1、截至2025年12月29日，广东宝莱特医用科技股份有限公司（以下简称"公 司"）股票已出现任意连续三十个交易日中至少有十五个交易日的收盘价低于 当期转股价格90%的情形。 2、公司于2025年12月29日召开第九届董事会第五次会议，审议通过了 ...

债券代码：123065 债券简称：宝莱转债 证券代码：300246 证券简称：宝莱特 公告编号：2025-086 1、证券代码：300246，证券简称：宝莱特 2、债券代码：123065，债券简称：宝莱转债 3、转股价格：23.97 元/股 4、转股期限：2021 年 3 月 11 日至 2026 年 9 月 3 日 根据《广东宝莱特医用科技股份有限公司创业板向不特定对象发行可转换公 司债券募集说明书》（以下简称"《募集说明书》"）规定：在本次发行的可转 换公司债券存续期间，当公司股票在任意连续三十个交易日中至少有十五个交易 日的收盘价低于当期转股价格的90%时，公司董事会有权提出转股价格向下修正 方案并提交公司股东会表决。 2025年12月9日至2025年12月22日，公司股票已有10个交易日的收盘价格低 于当期转股价格（23.97元/股）的90%，预计可能触发"宝莱转债"转股价格向下 修正条件。若触发转股价格向下修正条款，公司将按照《深圳证券交易所上市公 司自律监管指引第15号——可转换公司债券》的相关规定及《募集说明书》的约 定及时履行后续审议程序和信息披露义务。敬请广大投资者注意投资风险。 一、可转换 ...

Core Viewpoint - The A-share market shows positive momentum with the Shanghai Composite Index closing above the annual line, indicating a slight increase of 0.17% and a total trading volume of 1.665 trillion yuan [1]. Group 1: Market Performance - As of 14:59 today, the Shanghai Composite Index stands at 3876.97 points, above the annual line [1]. - A total of 153 A-shares have surpassed the annual line, with notable stocks showing significant deviation rates [1]. Group 2: Notable Stocks - The stocks with the highest deviation rates include: - Yimin Group (益民集团) with a deviation rate of 9.76% and a daily increase of 10.11% [1]. - Wanrun Technology (万润科技) with a deviation rate of 6.64% and a daily increase of 7.57% [1]. - Laiyifen (来伊份) with a deviation rate of 5.56% and a daily increase of 10.01% [1]. - Other stocks with smaller deviation rates that have just crossed the annual line include Suzhou Planning (苏州规划), Tianzhihang (天智航), and China Railway Special Cargo (中铁特货) [1].

Core Viewpoint - The company is expanding its overseas market presence for blood dialysis products, with a notable increase in overseas revenue expected by mid-2025 [1] Group 1: Overseas Market Expansion - The company has already established a presence in the overseas market for blood dialysis products, including blood dialysis equipment, dialyzers, and dialysate filters [1] - The overall scale of overseas operations is still small and in the expansion phase [1] - A significant growth of 121.29% in overseas blood dialysis revenue is anticipated by the first half of 2025, indicating positive business development [1] Group 2: Future Outlook - The company will continue to focus on and actively seize opportunities to expand its overseas blood dialysis market [1]

Company Overview - Guangdong Baolait Medical Technology Co., Ltd. was established in 1993, focusing on the R&D, production, and sales of medical devices. It is recognized as a national industrialization base for multi-parameter monitors and a national champion enterprise in manufacturing [1] - The company’s monitoring equipment is utilized in thousands of medical institutions, with a diverse product range including integrated monitors, modular monitors, and portable monitors, as well as infusion pumps and ECG machines [1] Product Development and Innovation - Recent product launches include the D800 series dialysis machines, P series modular monitors, home peritoneal dialysis machines, S series infusion pumps, and visual laryngoscopes, featuring industry-leading technologies [2][3] - The P series modular monitor won the "Red Dot Award" for its advanced features such as anti-electrosurgical interference technology and intelligent voice assistance [2] Market Trends and Policies - The "old-for-new" policy for medical devices positively impacts the company's monitoring equipment business, increasing demand for upgrades in public hospitals and grassroots medical institutions [4] - The policy encourages the replacement of outdated blood dialysis equipment, allowing the company to benefit from increased procurement in hospitals and private dialysis centers [5] Financial Performance - In the first three quarters of 2025, the subsidiary Suzhou Junkang reported revenue of CNY 74.15 million and a net profit of CNY 5.23 million, with production capacity gradually being released [6] - The company’s blood dialysis products have seen a 121.29% increase in overseas revenue in the first half of 2025, indicating a positive trend in international market expansion [8] Market Growth and Projections - The number of patients undergoing hemodialysis in 2024 is projected to reach 1.027 million, maintaining a compound annual growth rate of approximately 12% over the past decade [9][10] - The peritoneal dialysis market is also expected to grow, with patient numbers projected to increase by over 10% annually, driven by supportive policies and greater awareness [10] Conclusion - The company is well-positioned to capitalize on market opportunities through innovative product offerings and favorable government policies, aiming for enhanced market penetration and improved patient care outcomes [1][4][5]

Core Viewpoint - The article discusses the blood purification device industry, highlighting the increasing prevalence of End-Stage Renal Disease (ESRD) and the growth potential of blood purification technologies in response to this global health challenge [18][21]. Market Overview - The global ESRD patient population is projected to grow from 91.33 million in 2019 to 148.51 million by 2030, with a CAGR of 4.2% [18][19]. - In China, the ESRD patient population is expected to increase from 3.025 million in 2019 to 6.132 million by 2030, with a CAGR of 5.8% [20][18]. Treatment Methods - Blood purification is the most widely used treatment for ESRD, offering higher survival rates compared to kidney transplantation and conservative treatment [21]. - The number of patients receiving blood purification treatment in China rose from 736,000 in 2019 to 1.069 million in 2023, with a CAGR of 9.8%, and is expected to reach 3.791 million by 2030, with a CAGR of 19.8% [21][23]. Blood Purification Technologies - The main blood purification methods include hemodialysis, peritoneal dialysis, blood perfusion, and blood filtration, with hemodialysis being the most mature and widely applied [29]. - Hemodialysis effectively removes harmful substances and excess fluid from the blood, making it suitable for patients at various disease stages [29]. Market Size and Growth - The Chinese blood dialysis device market is projected to grow from CNY 11.63 billion in 2019 to CNY 51.52 billion by 2030, with a CAGR of 19.9% from 2023 to 2030 [30][28]. - The market share of blood dialysis devices in China is expected to see significant growth, with specific segments like blood dialysis machines and consumables also experiencing robust growth rates [30]. Competitive Landscape - Domestic companies are rapidly catching up with international competitors in the blood purification consumables sector, achieving nearly 50% market share in dialysis filters [31]. - The competitive landscape for blood dialysis machines is evolving, with domestic manufacturers improving their technology and performance to match imported products [37][33]. Policy and Market Dynamics - The article notes that the Chinese government has been implementing centralized procurement policies, leading to significant price reductions and accelerating the domestic replacement process in the blood purification market [36][35].

Investment Rating - The report does not explicitly provide an investment rating for the blood purification device industry Core Insights - The report highlights the increasing prevalence of End-Stage Renal Disease (ESRD) globally and in China, with the number of patients expected to rise significantly by 2030, indicating a growing market for blood purification devices [13][15] - Blood purification is identified as the most widely used treatment method for ESRD, with a higher survival rate compared to other treatments like kidney transplantation and conservative treatment [19] - The Chinese blood purification device market is projected to grow rapidly, driven by an increase in ESRD patients, improved reimbursement policies, and advancements in dialysis infrastructure [26] Market Overview - The global ESRD patient population increased from 9.13 million in 2019 to 11.14 million in 2023, with a CAGR of 5.1%, and is expected to reach 14.85 million by 2030 [13][14] - In China, the ESRD patient population grew from 3.03 million in 2019 to 4.13 million in 2023, with a CAGR of 8.1%, projected to reach 6.13 million by 2030 [15] - The number of patients receiving blood purification treatment in China rose from 736,000 in 2019 to 1.07 million in 2023, with a CAGR of 9.8%, expected to reach 3.79 million by 2030 [19][18] Treatment Methods - Blood purification methods include hemodialysis, peritoneal dialysis, blood perfusion, and blood filtration, with hemodialysis being the most common and effective method for ESRD patients [23] - Hemodialysis is noted for its effectiveness in removing toxins and excess fluid, while peritoneal dialysis is gaining traction due to its home treatment capabilities [21][23] Market Size and Growth - The Chinese blood purification device market size increased from 116.3 billion yuan in 2019 to 145.0 billion yuan in 2023, with a CAGR of 5.7%, and is expected to reach 515.2 billion yuan by 2030, with a projected CAGR of 19.9% from 2023 to 2030 [26] - The market for blood purification devices is segmented into blood purification machines, blood purification consumables, and other related equipment, with significant growth expected across all segments [26] Competitive Landscape - Domestic companies are rapidly catching up to international competitors in the blood purification consumables market, achieving nearly 50% market share in key areas [27] - The report indicates that the domestic market for blood purification machines still has room for growth, as these products have historically relied on imports due to high technical barriers [27][34] - The report emphasizes that domestic manufacturers are improving their technology and performance, positioning themselves to capture a larger market share [29][34]